Topical Steroids for Prevention of Diffuse Lamellar Keratitis Following LASIK by Farid Karimian et al.
 
Topical Steroids for Prevention of DLK; Karimian et al 
 
IRANIAN JOURNAL OF OPHTHALMIC RESEARCH 2007; Vol. 2, No. 2  119
Topical Steroids for Prevention of  
Diffuse Lamellar Keratitis Following LASIK  
Farid Karimian, MD; Hossein Yurdkhani, MD; Arash Anisian, MD;  
Mehrdad Mohammadpour, MD; Shahin Yazdani, MD 
Shaheed Beheshti Medical University, Tehran, Iran 
Purpose: To determine the role of prophylactic topical steroids in the prevention of 
diffuse lamellar keratitis (DLK) after laser in situ keratomileusis (LASIK). 
Methods: This randomized double blind clinical trial included consecutive LASIK 
candidates aged 18 to 55 years with stable (≥1 year) myopia ranging from -2 to -12 diop-
ters. The day before surgery, eyes were randomly allocated to topical betamethasone 
0.1% or placebo every four hours. One hour preoperatively, the dosage was increased to 
every five minutes for at least six times. DLK was graded according to the Linebarger-
Lindstorm classification. Patients were examined one week and one and three months 
after surgery. Best-corrected visual acuity (BCVA), manifest and cycloplegic refraction 
and severity of DLK were documented at each visit by a masked examiner. 
Results: Overall, 198 eyes (100 in the treatment group and 98 in the control group) of 101 
patients (97 bilateral and 4 unilateral cases) were operated. Pre- and post-LASIK 
refraction and BCVA were comparable in the study groups (P> 0.05). There were no 
significant complications in either group during or after LASIK except for DLK which 
developed in 55 eyes (55%) of the treatment group including 44 eyes with grade I and 11 
eyes with grade II, versus 36 eyes (36.7%) of the control group including 29 eyes with 
grade I and 7 eyes with grade II DLK (P= 0.81).  
Conclusion: Although steroids play a key role in the treatment of DLK, pretreatment 
with topical steroids 24 hours prior to LASIK does not seem prevent this complication.   
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INTRODUCTION 
 
Laser in situ keratomileusis (LASIK) has sur-
passed other types of refractive surgery over 
the past decade because of being easy to per-
form, rapid visual recovery and low incidence 
of pain and complications during and after the 
procedure.1 LASIK is widely used for treatment 
of moderate to high myopia (up to -10 diopters), 
low to moderate hyperopia and moderate reg-
ular astigmatism.2 
Although numerous intra- and post-
operative complications have been attributed   
to LASIK, the actual rate is very low. Diffuse 
lamellar keratitis (DLK) can occur shortly after 
LASIK and lead to irreversible visual loss in 
severe cases. This complication was first re-
ported by Smith and Maloney3 in 1998. It is a 
non-infectious inflammatory reaction in the 
flap-corneal bed interface which usually occurs 
one week after LASIK. Other names given to 
this syndrome include Sands of Sahara, Shifting  
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Sands, non-specific diffuse lamellar keratitis, 
sterile interface diffuse lamellar keratitis, post-
LASIK interface keratitis and lamellar keratitis.4 
But the term DLK which was used in the first 
report, appears more appropriate and is more 
commonly used.  
DLK has been reported by excimer laser 
centers all over the world, however the exact 
etiology still remains unknown5,6 but seems to 
be multifactorial.7 Contributing factors include 
meibomian gland secretions, povidone-iodine, 
talc powder from surgical gloves, remnants of 
antiseptics used for cleaning surgical instru-
ments, remnants of bacteria, endotoxins and 
exotoxins on surgical instruments, balanced salt 
solution (BSS), epithelial cells and red blood 
cells beneath the flap, polluted autoclave reser-
voirs and contaminations and deposits on the 
microkeratome.8-12  
Preventive measures against DLK have not 
been successful. The role of topical and sys-
temic steroids in the treatment of DLK and pre-
vention of its progression have been studied.13 
In one study, topical steroids were used after 
lifting the flap and before laser application 
which seemed to decrease the risk of DLK.14 
The role of lid scrubbing and treatment of ble-
pharitis prior to LASIK as well as use of sys-
temic steroids and antihistamines in atopic in-
dividuals has already been established.15 How-
ever, the role of topical steroids prior to LASIK 
for prevention of DLK has not been studied yet.  
An episodic increase in the rate of DLK 
was seen in excimer centers in Tehran during 
the years 2002 to 2004 with no particular causa-
tive factor (unpublished data). This research 
was performed during the year 2004 at Negah 
Eye Center, Tehran, Iran during an outbreak of 
DLK to evaluate the role of preoperative topical 
steroids for prevention of DLK. 
 
METHODS 
 
This double blind randomized clinical trial was 
conducted on a consecutive series of patients 18 
to 55 years of age undergoing LASIK. A com-
plete ophthalmologic examination was perfor-
med in all patients including uncorrected visual 
acuity (UCVA), manifest and cycloplegic ref-
raction, best spectacle-corrected visual acuity 
(BSCVA) using Nidek projection chart (Nidek, 
Kamagori, Japan), slitlamp examination, Gold-
mann applanation tonometry and funduscopy 
with a fully dilated pupil. Refraction and cor-
neal topography (if available) were stable for at 
least one year. The patients had no other ocular 
condition other than refractive errors and no 
systemic disorders. Contact lenses were discon-
tinued at least one and three weeks before vi-
deokeratography in soft and rigid gas per-
meable (RGP) lens wearers, respectively. All 
patients were instructed to scrub their eyelids 
with baby shampoo three days before surgery. 
The study and its purpose were explained 
to all patients and informed consent was ob-
tained. All subjects underwent computerized 
videokeratography (CSO, Italy), ultrasonic 
pachymetry (Somoned, USA) and Orbscan II 
topography (Bausch & Lomb, Germany) three 
days before LASIK. Topical betamethasone 
0.1% eyedrops (Chauvin, France) were pres-
cribed for eyes in the treatment group and 
placebo was administered to the control eyes 
every four hours one day prior to LASIK and 
every five minutes for at least six times one 
hour before the procedure. In bilateral LASIK 
candidates, one eye was randomized for treat-
ment and the fellow eye received placebo. 
All LASIK procedures were performed   
by one surgeon (FK) under topical anesthesia 
with 0.5% tetracaine. The Moria LSK Carriaso-
Barraquer microkeratome (Moria, France) with 
a fixed plate was used to cut a flap of 160 
micron thickness. Each microkeratome blade 
(Moria, France) was used once for each patient 
(i.e., for both eyes in bilateral cases) after 
cleaning by distilled water and wet spears and 
checking for any deposit or irregularities under 
the surgical microscope immediately before 
surgery. After creation of the flap and making 
sure of its normalcy and central position, laser 
ablation was performed using the Nidek EC-
5000 CX-II (Nidek, Kamagori, Japan) excimer 
laser machine. The flap was then returned to its 
position and the undersurface was irrigated 
with a small amount of BSS until there was no  
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visible debris or foreign particles. After per-
forming LASIK on the first eye, if there was no 
complication and the patient agreed, the pro-
cedure was performed in the fellow eye in bila-
teral cases. At the end of the operation, betame-
thasone and chloramphenicol eyedrops were 
instilled in the operated eye and continued 
every six hours. Chloramphenicol was discon-
tinued after one week and betamethasone dos-
age was adjusted as described subsequently. 
  Postoperative examinations were perfor-
med by one masked observer, unaware of the 
treatment allocation of patients. Uncomplicated 
patients were visited every day during the first 
week and one and three months thereafter. 
Betamethasone dosage was adjusted according 
to degree of inflammation and grade of DLK 
based on Linstrom-Linebarger classification.16 
In the absence of DLK, betamethasone was 
gradually tapered and discontinued over two 
weeks. In the presence of DLK, treatment was 
continued based on DLK grading: in grade I, 
betamethasone frequency was increased to 
hourly. Grade II DLK was treated with beta-
methasone drops every one hour and beta-
methasone ointment at night together with oral 
prednisolone 1 to 1.5 mg/kg/day. The systemic 
steroid was discontinued over 7-10 days after 
control of DLK.  
Severity of pain during the first six hours 
after LASIK was subjectively graded based on a 
0 to 10-scale measure where zero and 10 indi-
cated no and very severe pain, respectively. 
UCVA, BSCVA, refraction, slitlamp examina-
tion and tonometry were repeated one and 
three months postoperatively. Statistical ana-
lysis was done using paired and unpaired   
t-tests for mean values within and between the 
two groups, respectively and Chi-square test 
for frequency values with significance set at 
P<0.05. 
 
RESULTS  
 
From July to September 2004, 198 eyes (100   
in the treatment group and 98 in the control 
group) of 101 patients (97 bilateral and 4 uni-
lateral cases) with mean age of 30±12.7 (range 
18–51) years were enrolled in this study. 
Seventy-five patients were female. Only one 
case was referred for enhancement surgery and 
others were new LASIK candidates. Each group 
included three hyperopic eyes which were 
excluded from data analysis due to the small 
number.  
Pain score greater than four (mild) within 
the first six hours after LASIK was reported in 
four eyes of the treatment group and seven 
eyes of the control group (P<0.05). There was 
no case of severe pain in any group. 
DLK occurred in 55 eyes (55%) including 
44 (80%) grade I and 11 (20%) grade II in the 
treatment group and in 36 eyes (36.7%) in-
cluding 29 (81%) grade I and 7 (19%) grade II in 
the control group (P=0.81). No case of grade III 
or higher DLK was observed in any group. 
Mean spherical equivalent (SE) refraction 
in the treatment and control groups was   
-4.8±2.4 and -5.2±2.7 diopters (D) respectively 
(P=0.16). One week postoperatively, mean SE 
was -0.41±0.27 D and -0.42±0.39 D in the treat-
ment and control groups, respectively (P=0.84). 
Mean UCVA was 0.09±0.6 and 0.07±0.05 
LogMAR in the treatment and control groups, 
respectively (P=0.41) (Table 1). 
 
Table 1 Uncorrected visual acuity one week after 
laser in situ keratomileusis 
  Treatment group Control group  
20/15 to 20/25  89 (90.8%)  83 (86.3%) 
20/25 to 20/50  9 (9.2%)  11 (11.6%) 
<20/50  0  2 (2.1%) 
Total  98 (100%)  96 (100%) 
•Fisher exact test, P= 0.41 
 
 
Three months postoperatively, 65 cases in-
cluding 24 in the treatment group and 36 in the 
control group were available for final evalu-
ation. Mean SE was -0.36±29 D and -0.49±31 D 
in the treatment and control groups respect-
tively (P=0.29). Mean UCVA was 0.09±0.04 
LogMAR in the treatment group and 0.07±0.04 
LogMAR in the control group (P=0.28). At final 
follow-up, no eye lost more than one line of 
BCVA; no irregular astigmatism was noted and  
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no patient complained of glare or ghost images. 
No case of corneal opacity, epithelial ingrowth, 
folds in the flap crossing the visual axis, flap 
displacement, infectious keratitis, cataract or 
IOP rise was seen.  
 
DISCUSSION 
 
LASIK is probably the most common kerato-
refractive procedure. The rate of post-LASIK 
complications has been reported from 3 to 
12%.4,5,7  DLK is usually a mild and transient 
condition but in severe cases may cause corneal 
scarring, irregular astigmatism and decreased 
vision. Multiple factors have been implicated in 
the development of DLK.7-12,17 This condition 
seems to be an immunologic or inflammatory 
response of the cornea to antigens or debris in-
troduced beneath the flap during the operation. 
Some authors believe that suppressing the im-
mune response with steroids (topical and sys-
temic) may control or prevent DLK.13 Several 
prophylactic measures have been investigated, 
but due to the multifactorial nature of DLK, 
none has been definitely effective. In one study 
on atopic cases, with a postulated higher 
chance of DLK, prophylactic antihistamine 
(Loratadine) reduced the incidence of DLK.15  
In the current study, topical steroids had 
no role in preventing DLK; there was no statis-
tically significant difference between treatment 
and placebo groups regarding occurrence of 
DLK or final refraction. It is thought that fre-
quent administration of topical steroids before 
LASIK may predispose the eye to infectious 
keratitis, one of the most severe and serious 
complications of LASIK, especially bacterial 
keratitis which is more common early after 
surgery. However, over three months of follow-
up, we did not encounter any case of infectious 
keratitis in our series.  
Overall, grade I and II DLK were seen in 
36.5% and 9.1% of eyes in our study, res-
pectively. The rate of grade I DLK has been 
reported less than 1% by Johnson et al 6, 2-4% 
by Linebarger et al16, 4% by Stulting et al18 and 
9% by Wilson et al.19 The incidence of grade II 
DLK has been reported from 0.18 to 0.5% in the 
above-mentioned studies. The difference in the 
incidence of DLK between our center in Tehran 
and other excimer centers around the world   
is unexplainable. Keratorefractive surgeons at 
different laser centers in Tehran have sought 
several remedies to control DLK outbreaks 
such as using different laser machines, different 
microkeratome blades, spears and irrigation 
solutions (Ringer vs BSS), avoiding ultra- 
sound sterilization, chemical sterilization, use 
of powder-free gloves, regular cleaning and 
drying of the autoclave reservoir, stromal-flap 
bed irrigation with steroid containing solutions. 
The exact cause of the epidemic outbreaks of 
DLK in this city however remains unknown.  
It has been postulated that prophylactic 
topical steroids can prevent DLK, but no de-
finite study has been reported in this regard. 
Our study was not able to prove that topical 
steroids before LASIK can prevent this comp-
lication, however one may argue that initiation 
of topical steroids one day before LASIK may 
not be early enough to suppress the immuno-
logical response and prevent DLK. Cosar et   
al20 have shown that early postoperative   
use of high frequency topical steroids can pre-
vent DLK. They used prednisolone acetate or 
dexamethasone eye drops every hour after 
LASIK which was able to prevent epidemic 
DLK. Administration of non-steroidal anti-
inflammatory drugs or corticosteroids in an 
animal model was also able to prevent or 
reduce DLK.21 
In summary, topical administration of cor-
ticosteroids prior to LASIK did not prevent 
DLK. At the present time, the best way for pre-
vention of DLK is to eliminate defined predis-
posing factors for DLK. Close follow-up during 
the early postoperative period for early diag-
nosis and treatment of this potentially sight-
threatening complication may prevent per-
manent corneal damage.   
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